NextPoint Therapeutics, Inc.
Rachel O'Connor is an accomplished professional in the field of Translational Immuno-Oncology with extensive experience across multiple biotech and pharmaceutical companies. Currently serving as Associate Director of Translational Operations at NextPoint Therapeutics, Inc., Rachel's previous roles include Senior Scientist at KSQ Therapeutics, Inc., Research Investigator and Associate Scientist II at Surface Oncology Inc., and Scientific Associate at Novartis Institutes for BioMedical Research. Rachel's foundational experience includes research on HIV eradication strategies at the Ragon Institute of MGH, MIT and Harvard, where responsibilities ranged from independent assay design to lab management. Early career experience as a Pharmacy Technician at Newton-Wellesley Hospital further enhances Rachel's comprehensive skill set. Rachel holds a Bachelor of Science in Cell/Cellular and Molecular Biology from Syracuse University.
NextPoint Therapeutics, Inc.
NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells.